2 results
Approved WMOCompleted
The primary objective is to compare PFS after treatment with tabalumab, bortezomib, anddexamethasone to that of placebo, bortezomib, and dexamethasone in patients with relapsed/refractory MM.Secondary objectives will include comparison of treatment…
Approved WMOPending
The objective of this study is to evaluate the dose-ranging response in safety and efficacy of R115866 0.5mg, 1mg and 2mg and R115866 placebo given once daily for the treatment of subjects with plaque psoriasis to select a dose for further clinical…